Literature DB >> 35663682

Voriconazole Induced Cutaneous Squamous Cell Carcinoma in an Immunocompetent Patient.

Kevin Parza1, Pratishtha Singh1, Jessica Cvinar1, Terence Zimmerman2, Brian Watson3, Mohamed Faris1.   

Abstract

Voriconazole therapy can be associated with hair loss, vision changes, and skin phototoxicity, but rarely is it associated with the development of skin cancer. We present a case of an immunocompetent 42-year-old Caucasian male with a past medical history significant for chronic pulmonary aspergillosis (CPA) and prior cutaneous squamous cell carcinoma (cSCC) of the left hand who arrived at our clinic for evaluation of an enlarging, non-tender left preauricular mass over the past six months. He had diffuse actinic changes and appeared older relative to his age. He had a fair complexion but was compliant with sun protection measures and minimized unnecessary ultraviolet (UV) light exposure. His left-sided facial mass was excised, and the final pathology was consistent with cSCC. His only home medication was oral voriconazole 200 mg once daily for six years for pulmonary aspergillosis. He was negative for human immunodeficiency virus (HIV) and had no history of prior transplant operations. This case highlights the importance of recognizing voriconazole as an independent risk factor in the development of cSCC, especially in patients on chronic therapy for aspergillosis.
Copyright © 2022, Parza et al.

Entities:  

Keywords:  cutaneous squamous cell carcinoma; mass; parotid mass; photosensitivity reaction; pulmonary aspergillosis; radiation therapy; voriconazole

Year:  2022        PMID: 35663682      PMCID: PMC9153335          DOI: 10.7759/cureus.25508

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  15 in total

1.  Antifungal prophylaxis in lung transplantation--a world-wide survey.

Authors:  C F Neoh; G I Snell; T Kotsimbos; B Levvey; C O Morrissey; M A Slavin; K Stewart; D C M Kong
Journal:  Am J Transplant       Date:  2011-01-10       Impact factor: 8.086

2.  Fever and eosinophilia associated with voriconazole.

Authors:  Priya Vishnubhotla; Rami B Ibrahim; Muneer Hyder Abidi; Pranatharthi H Chandrasekar
Journal:  Ann Pharmacother       Date:  2004-03-23       Impact factor: 3.154

3.  Voriconazole Exposure and Risk of Cutaneous Squamous Cell Carcinoma, Aspergillus Colonization, Invasive Aspergillosis and Death in Lung Transplant Recipients.

Authors:  M Mansh; M Binstock; K Williams; F Hafeez; J Kim; D Glidden; R Boettger; S Hays; J Kukreja; J Golden; M M Asgari; P Chin-Hong; J P Singer; S T Arron
Journal:  Am J Transplant       Date:  2015-09-03       Impact factor: 8.086

4.  Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management.

Authors:  David W Denning; Jacques Cadranel; Catherine Beigelman-Aubry; Florence Ader; Arunaloke Chakrabarti; Stijn Blot; Andrew J Ullmann; George Dimopoulos; Christoph Lange
Journal:  Eur Respir J       Date:  2016-01       Impact factor: 16.671

Review 5.  Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection.

Authors:  D E Rowe; R J Carroll; C L Day
Journal:  J Am Acad Dermatol       Date:  1992-06       Impact factor: 11.527

Review 6.  Voriconazole-associated cutaneous malignancy: a literature review on photocarcinogenesis in organ transplant recipients.

Authors:  Kiyanna Williams; Matthew Mansh; Peter Chin-Hong; Jonathan Singer; Sarah Tuttleton Arron
Journal:  Clin Infect Dis       Date:  2013-12-20       Impact factor: 9.079

7.  Adverse effects of voriconazole: analysis of the French Pharmacovigilance Database.

Authors:  Céline Eiden; Hélène Peyrière; Marylène Cociglio; Samira Djezzar; Sylvie Hansel; Jean-Pierre Blayac; Dominique Hillaire-Buys
Journal:  Ann Pharmacother       Date:  2007-04-24       Impact factor: 3.154

8.  Voriconazole and squamous cell carcinoma after lung transplantation: A multicenter study.

Authors:  B Hamandi; C Fegbeutel; F P Silveira; E A Verschuuren; M Younus; J Mo; J Yan; P Ussetti; P V Chin-Hong; A Solé; C L Holmes-Liew; E M Billaud; P A Grossi; O Manuel; D J Levine; R G Barbers; D Hadjiliadis; J Aram; L G Singer; S Husain
Journal:  Am J Transplant       Date:  2017-10-16       Impact factor: 8.086

Review 9.  Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents.

Authors:  Roger J M Brüggemann; Jan-Willem C Alffenaar; Nicole M A Blijlevens; Eliane M Billaud; Jos G W Kosterink; Paul E Verweij; David M Burger
Journal:  Clin Infect Dis       Date:  2009-05-15       Impact factor: 9.079

10.  Twelve-month clinical outcomes of 206 patients with chronic pulmonary aspergillosis.

Authors:  Felix Bongomin; Chris Harris; Gemma Hayes; Chris Kosmidis; David W Denning
Journal:  PLoS One       Date:  2018-04-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.